Inflammasome: Activation mechanisms;El inflamasoma: Mecanismos de activación

Investigacion Clinica (Venezuela)

Volumn 56, Issue 1, 2015, Pages 74-99

  Suárez, Raibel ^a   Buelvas, Neudo ^a  

^a HOSPITAL UNIVERSITARIO DE MARACAIBO   (Venezuela)

Author keywords

Canonical; Caspase 1; IL 1 ; Inflammasome; Inflammation; NALP3

Indexed keywords

ADENOSINE TRIPHOSPHATE; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 8; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; PROCASPASE 1; PROTEIN PRECURSOR; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CARRIER PROTEIN; CYTOKINE; NLRP1 PROTEIN, HUMAN; NLRP2 PROTEIN, HUMAN; NLRP3 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; GOUT; HYPERHOMOCYSTEINEMIA; HYPERTENSION; IMMUNE SYSTEM; INFLAMMATION; MALARIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION REDUCTION REACTION; PATHOGENESIS; TISSUE REPAIR; HUMAN; PHYSIOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; CYTOKINES; HUMANS; INFLAMMASOMES;

EID: 84931410659     PISSN: 05355133     EISSN: 05355133     Source Type: Journal    
DOI: None     Document Type: Article

References (104)

1. Turk JL. Inflammation: John Hunter's a treatise on the blood, inflammation and gun-shot wounds. Int J Exp Path 1994; 75: 985-995.
2. Franchi L, Kamada N, Nakamura Y, Burberry A, Kuffa P, Suzuki S, Shaw M, Kim YG, Núñez G. NLRC4-driven interleukin- 1β production discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat Immunol 2012; 13(5): 449-456.
3. Kolli D, Velayutham T, Casola A. Host-Viral Interactions: Role of pattern recognition receptors (PRRs) in human pneumovirus Infections. Pathogens 2013; 2(2):1- 30.
4. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 2009; 21 (4): 317-337.
5. Hardison S, Brown G. C-type lectin receptors orchestrate anti-fungal immunity. Nat Immunol 2012; 13(9): 817-822.
6. De Rivero J, Lotocki G, Marcillo A, Dietrich D, Keane R. A molecular platform in neurons regulates inflammation after spinal cord injury. J Neuro Sci 2008; 28(13): 3404-3414.
7. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004; 430: 257-263.
8. Bromfield J, Sheldon M. Lipopolysaccharide initiates inflammation in bovine granulosacells via the TLR4 pathway and perturbs oocyte meiotic progression in vitro. Endocrinology 2011; 152(12): 5029- 5040.
9. Reynolds J, Martinez G, Chung Y, Dong C. Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation. PNAS 2012; 109 (32): 13064-13069.
10. Campanholle G, Mittelsteadt K, Nakagawa S, Kobayashi A, Lin SL, Gharib S, Heinecke J, Hamerman J, Altemeiers W, Duffield J. TLR-2/TLR-4 TREM-1 signaling pathway is dispensable in inflammatory myeloid cells during sterile kidney injury. PLoS One 2013; 8(7): 1-12.
11. Turner C, Arulkumaran N, Singer M, Uewin R, Tam F. Is the inflammasome a potential therapeutic target in renal disease? BMC Nephrol 2014; 15 (21): 1-13.
12. Ting J, Kastner D, Hoffman H. CATERPILLERs, Pyrin and hereditary immunological disorders. Nature Rev Immunol 2006; 6: 183-195.
13. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10: 417-426.
14. Sakhon O, Victor K, Choy A, Tsuchiya T, Eulgem T, Pedra J. NSD1 Mitigates caspase-1 activation by listeriolysin O in macrophages. PLoS One 2013; 8 (9): 1-12.
15. Vajjhala P, Mirams R, Hill J. Multiple binding sites on the pyrin domain of ASC protein allow self-association and interaction with NLRP3 protein. J Biol Chem 2012; 287(50): 41732-41743.
16. Halff E, Diebolder C, Versteeg M, Schouten A, Brondijk H, Huizinga E. Formation and structure of a NAIP5-NLRC4 inflammasome induced by direct interactions with conserved n- and c-terminal regions of flagellin. J Biol Chem 2012; 287 (46): 38460-38472.
17. Segovia J, Sabbah A, Mgbemena V, Tsai SY, Chang TH, Berton M., Morris I, Allen I, Ting J, Bose S. TLR2/MyD88/NF-κB pathway, reactive oxygen species, potassium efflux activates NLRP3/asc inflammasome during respiratory syncytial virus infection. PLoS One 2012; 7(1): 1-15.
18. Minkiewicz J. ATP activation of the NLRP2 inflammasome in human astrocytes. [Tesis Doctoral] Miami: Univ. of Miami; 2013.
19. Jin C, Flavell R, Molecular mechanism of nlrp3 inflammasome activation. J. Clin Immunol 2010. 30:628-631.
20. Holbourn K, Shone C, Acharya K. A family of killer toxins exploring the mechanism of ADP-ribosylating toxins. FEBS J 2006; 273: 4579-4593.
21. Khakh B, North A, P2X receptors as cell-surface ATP sensors in health and disease. Nature 2006; 442 (3): 527-532.
22. Di Virgilio F, Liaisons dangereuses: P2X7 and the inflammasome. Trends Pharmacol Sci 2007; 28 (9): 465-472.
23. Sun S, Xia S, Ji Y, Kersten S, Qi L. The ATP-P2X7 signaling axis is dispensable for obesity-associated inflammasome activation in adipose tissue. Diabetes 2012; 61: 1471-1478.
24. Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signaling pathways on ROS production? Nature Rev Immunol 2010; 10: 210-215.
25. Hung S, Choi C, Said N, Johnson K, Atanasova K, Sellami H, Yilmaz O, Ojcius D. P2X4 assembles with P2X7 and pannexin-1 in gingival epithelial cells and modulates ATP-induced reactive oxygen species production and inflammasome activation. PLoS One 2013; 8 (7): 1-12.
26. Fernandes T, Wu J, Yu J, Datta P, Miller B, Jankowski, Rosemberg S, Zhang J, Alnemri E. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ 2007; 14(9): 1590-1604.
27. Silverman W, De Rivero J, Locovei S, Qiu F, Carsson S, Scemes E, Keane R, Dahl G. The pannexin-1 channel activates the inflammasome in neurons and astrocytes. J Biol Chem 2009; 284(27): 18143-18151.
28. Craven R, Gao X, Allen I, Gris D, Wardenburg JB, McEvania-Tekippes E, Ting J, Duncan J. Staphylococcus aureus α-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells. PLoS One 2009; 4 (10): 1-11.
29. De Rivero J, Bastien D, Yurcisin G, Pineau I, Dietrich W, Dekoninck Y, Keane R, Lacroix S. P2X4 receptors influence inflammasome activation after spinal cord injury. J Neurosci 2012; 32(9): 3058-3066.
30. Weinhold K, Krause U, Rödel G, Kasper M, Barth K. Interaction and interrelation of P2X7 and P2X4 receptor complexes in mouse lung epithelial cells. Cell Mol Life Sci 2010; 67(15): 2631-2642.
31. Hornung V, Bauernfeind F, Halle A, Samstad E, Kono H, Rock K, Fitzgerald K, Latz E. Silica crystals and aluminum salts mediate NALP-3 inflammasome activation via phagosomal destabilization. Nat Immunol 2008; 9(8): 847-856.
32. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010; 11 (2):136-140.
33. Spindel O, World C, Berk B. Thioredoxin interacting protein: redox dependent and independent regulatory mechanisms. Antioxid Redox Signal 2012; 16 (6): 587-596.
34. Rodriguez B, Nosratola V, Herrera J, Johnson R. Oxidative stress, renal Infiltration of immune cells, and salt-sensitive hypertension: All for one and one for all. Am J Physiol Renal Physiol 2004; 286:606-616.
35. Levandowski C, Mailloux C, Ferrara T, Gowan K, Ben S, Jin Y, McFann K, Holland P, Fain P, Dinarello C, Spritz R. NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1β processing via the NLRP1 inflammasome. PNAS 2013; 110 (8): 2952-2956.
36. Latz E., Xiao T, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013; 13(6): 1-30.
37. Finger J, Lich J, Dare L, Cook M, Brown K, Duraiswami C, Bertin J, Gough P. Autolytic proteolysis within the function to find domain (FIIND) is required for NLRP1 inflammasome activity. J Biol Chem 2012; 287 (30): 25030-25037.
38. Frew B, Joag V, Mogridge J. Proteolytic Processing of Nlrp1b is required for inflammasome activity. PLoS Pathog 2012; 8 (4): 1-11.
39. Mankan A. Kubarenko A, Hornung V. Immunology in clinic review series; focus on autoinflammatory diseases: inflammasomes: mechanisms of activation. Clin Exp Immunol 2011; 167: 369-381.
40. García M, Guerrero G, Castro M, Medina C. Inmunomoduladores como terapia adyuvante en la enfermedad infecciosa. Med Univer 2009; 11(45):247-259.
41. Mo J, Boyle J, Howard C, Monie T, Davis B, Duncan J. Pathogen sensing by nucleotide- binding oligomerization domain-containing protein 2 (NOD2) is mediated by direct binding to muramyl dipeptide and ATP. J Biol Chem 2012; 287(27): 23057- 23067.
42. Witola W, Mui E, Hargrave A, Liu S, Hypolite M, Montpetit A. NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondiiinfected monocytic cells. Infect Immun 2011; 79 (2): 756-766.
43. Liu F, Lo C, Ning X, Kajkowski E, Jin M, Chiriac C, Gonzales C, Naureckiene S, Lock Y, Pong K, Zaleska M, Jacobsen J, Silverman S, Ozenberger V. Expression of NALP1 in cerebellar neurons stimulates apoptosis. Cell Signal 2004; 16(9): 1013- 1021.
44. Bertin J, DiStefano P. The PYRIN domain: a novel motif found in apoptosis and inflammation proteins. Cell Death Differ 2000; 7(12): 1273-1274.
45. Bruey J, Bruey N, Newman R, Chandler S, Stehlik C, Reed J. PAN1/NALP2/PYPAF2, an inducible inflammatory mediator that regulates NF-κB an caspase-1 activation in macrophages. J Biol Chem 2004; 279(50): 51897-51907.
46. Minkiewicz J, De Rivero J, Keane R. Human astrocytes express a novel NLRP2 inflammasome. Glia 2013; 61(7): 1113- 1121.
47. Conti B, Davis B, Zhang J, O'Connor W, Williams K, Ting Y. CATERPILLER 16.2 (CLR16.2), a novel NBD/LRR family member that negatively regulates T cell function. J Biol Chem 2005; 280: 18375- 18385.
48. Grenier J, Wang L, Manji G, Huang W, Al-Garawi A, Kelly R, Carlson A, Merrian S, Lora J, Briskin M, DiStefano P, Bertin J. Functional screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF-kappaB and caspase-1. FEBS Lett 2002; 503(1-3): 73-78.
49. Ratsimandresy R, Dorfleutner A, Stehlik C. An update on PYRIN domain-containing pattern recognition receptors: from immunity to pathology. Front Immunol 2013; 4: 1-20.
50. Lightfield K, Persson J, Trinidad N, Brubaker S, Kofoed E, Sauer JD, Dunipace E, Warren S, Miao E, Vance R. Differential requirements for NAIP5 in activation of the NLRC4 Inflammasome. Infect Immun 2011; 79 (4): 1606-1614.
51. Kofoed E, Vance R. Innate immune recognition of bacterial ligands by NAIPs dictates inflammasome specificity. Nature 2012; 477(7366): 592-595.
52. Wen H, Miao E, Ting J. Mechanism of NOD- like receptor- associated inflammasome activation. Immunity 2013; 39: 432-441.
53. Savage C, Lopez G, Denes A, Brough D. NLRP3-inflammasome activating DAMPs stimulate an inflammatory response in glia in the absence of priming which contributes to brain inflammation after injury. Front Immunol 2012; 3 (288):1-11.
54. Inoue M, Williams K, Gunn M, Shinohara M. NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. PNAS 2012 109 (26): 10480-10485.
55. Jin T, Curry J, Smith P, Jiang J, Xiao S. Structure of the NLRP1 caspase recruitment domain suggests potential mechanisms for its association with procaspase-1. Proteins 2013; 81(7): 1-8.
56. Srinivasula S, Poyet JL, Razmara M, Datta P, Zhang Z, Alnemri E. The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J Biol Chem 2002; 277(24): 21119-21122.
57. Scott AM, Saleh M. The inflammatory caspases: guardians against infections and sepsis. Cell Death Differ 2007; 14: 23-31.
58. Burns K, Martinon F, Tschopp J. New insights into the mechanism of IL-1β maturation. Curr Opin Immunol 2003; 15: 26-30.
59. Fernandes T, Yu JW, Wu J, Datta P, Alnemri E. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009; 458(7237): 509-513.
60. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140:821-832.
61. Hornung V, Ablasser A, Denni MC, Bauernfeind F, Hovarth G, Caffrey D, Latz E, Fitzgerald K. AIM2 recognizes cytosolic dsDNA and forms a caspase-1 activating inflammasome with ASC. Nature 2009; 458(7237): 514-518.
62. Brunette R, Young J, Whitley D, Brobdsky I, Malik H, Stetson D. Extensive evolutionary an functional diversity among mammalian AIM-2-like receptors. J Exp Med 2012; 209(11): 1969-1983.
63. Cridland J, Curley E, Wykes M, Schroder K, Sweet M, Roberts T, Ragan M, Kassahn K, Stacey K. The mammalian PYHIN gene family: phylogeny, evolution and expression. BMC Evol Biol 2012; 12:1-17.
64. Albrecht M, Choubey D, Lengauer T. The HIN domain of IFI-200 proteins consists of two OB folds. Biochem Biophys Res Commun 2005; 327 (3): 679-687.
65. Lee J, Li N, Gretz N, Gebert J, Dihlmann S. Absent in melanoma 2 (AIM2) is an important mediator of interferon-dependent and -independent HLA-DRA and HLA-DRB gene expression in colorectal cancers. Oncogene 2012; 31: 1242-1253.
66. Juruj C, Lelogeais V, Pierini R, Perret M, Py BF, Jamilloux Y, Broz P, Ader F, Faure M, Henry T. Caspase-1 activity affects AIM2 speck formation/stability through a negative feedback loop. Front Cell Infect Microbiol 2013; 3(14): 1-11.
67. Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 2008; 121(5): 1108-1111.
68. Huang TT, Chong KY, Ojcius D, Wu YH, Ko YF, Wu CY, Martel J, Lu CC, Lai HC, Young J. Hirsutella sinensis mycelium suppresses interleukin-1b and interleukin-18 secretion by inhibiting both canonical and non-canonical inflammasomes. Sci Rep 2013; 3: 1374: 1-11.
69. Dinarello C.A, Novick D, Kim S, Kaplansky G. Interleukin-18 and IL-18 binding protein. Front Immunol 2013; 8; 4(289): 1-10.
70. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009; 27: 229-265.
71. Akhter A, Caution K, Abu A, Tazi M, Abdulrahman B, Abdelasiz D, Vozz O, Doseff A, Hassan H, Azad A, Schlesingel L, Wewers M, Gavrilim M, Amer A. Caspase-11 promotes the fusion of phagosomes harboring pathogenic bacteria with lysosomes by modulating actin polymerization. Immunity 2012; 37: 35-47.
72. Sollberger G, Strittmatter GE, Kistowska M, French LE, Beer HD. Caspase-4 is required for activation of inflammasomes. J Immunol 2012; 188(4): 1992-2000.
73. Kayagaki N, Warming S, Lamkanfi M, Van de Walle L, Louie S, Dong J, NewtonK, Qu Y, Liu J, Heldens S, Zhang J, Lee W, Rose M, Dixit V. Non-canonical inflammasome activation targets caspase-11. Nature 2011; 479: 117-121.
74. Casson C, Copenhaver A, Zwack E, Nguyen H, Strowig T, Javdan B, Bradley W, Fung T, Flavell R, Brodsky I, Shin S. Caspase-11 activation in response to bacterial secretion systems that access the host cytosol. PLoS Pathog 2013; 9 (6):1-16.
75. Broz P, Monack D. Noncanonical inflammasomes: caspase-11 activation and effector mechanisms. PLoS Pathog 2013; 9 (2): 1-9.
76. Keller M, Ruegg A, Werner S, Beer H. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008; 132: 818-831.
77. Bergsbaken T, Fink S, Cookson B. Pyroptosis: host cell death and inflammation Nat Rev Microbiol 2009; 7: 99-109.
78. Gringhuis SI, Kaptein TM, Wevers BA, Theelen B, Van der Vlist M, Boekhout T, Geijtenbeek TB. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1β via a noncanonical caspase-8 inflammasome. Nat Immunol 2012; 13(3):246-254.
79. Maelfait J, Vercammen E, Janssens S, Schotte P, Haegman M, Magez S, Beyaert R. Stimulation of Toll-like receptor 3 and 4 induces interleukin-1beta maturation by caspase-8. J Exp Med 2008; 205(9): 1967- 1973.
80. Hara H, Tsuchiya K, Kawamura I, Fang R, Hernandez-Cuellar E, Shen Y, Mizuguchi J, Schweighoffer E, Tybulewicz V, Mitsuyama M. Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity. Nat Immunol 2013; 12: 1247-1255.
81. Franchi L, Eigenbrod T, Nuñez G. Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J Immunol 2009; 183: 792- 796.
82. Juliana C, Fernandes T, Kang S, Farias A, Qin F, Alnemri ES. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem 2012; 287(43): 36617-36622.
83. Py BF, Kim MS, Vakifahmetoglu-Norberg H, Yuan J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol Cell 2013; 49 (2): 331-338.
84. Qu Y, Misaghi S, Izrael-Tomasevic A, Newton K, Gilmour LL, Lamkanfi M, Louie S, Kayagaki N, Liu J, Kömüves L, Cupp JE, Arnott D, Monack D, Dixit VM. Phosphorylation of NLRC4 is critical for inflammasome activation. Nature 2012; 490 (7421): 539-542.
85. Lu B, Nakamura T, Inouye K, Li J, Tang Y, Lundbäck P, Valdes-Ferrer SI, Olofsson PS, Kalb T, Roth J, Zou Y, Erlandsson-Harris H, Yang H, Ting JP, Wang H, Andersson U, Antoine DJ, Chavan SS, Hotamisligil GS, Tracey KJ. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 2012; 488 (7413): 670-674.
86. Haneklaus M, O'Neill LA, Coll RC. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Curr Opin Immunol 2013; 25 (1): 40-45.
87. Bauernfeind F, Rieger A, Schildberg FA, Knolle PA, Schmid-Burgk JL, Hornung V. NLRP3 inflammasome activity is negatively controlled by miR-223. J Immunol 2012; 189 (8): 4175-4181.
88. Lee G, Subramanian N, Kim A, Aksentijevich I, Goldbach-Mansky R, Sacks DB, Germain RN, Kastner DL, Chae J. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature 2012; 492 (7427): 123-127.
89. Compan V, Baroja-Mazo A, López- Castejón G, Gómez AI, Martínez CM, Angosto D, Montero MT, Herranz AS, Bazán E, Reimers D, Mulero V, Pelegrín P. 2012. Cell volume regulation modulates NLRP3 inflammasome activation. Immunity 2012; 37(3): 487-500.
90. Zhang C, Boini K, Xia M, Abais J, Li X, Liu Q, Li PL. Activation of NALP3 inflammasomes turns on podocyte injury and glomerular sclerosis in hyperhomocysteinemia. Hypertension 2012; 60(1): 154-162.
91. Lee H, Kim J, Kim H, Shong M, Ku B, Jo E. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013; 62: 194-204.
92. Ghaemi F, Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr Rheumatol Rep 2011; 13(2): 160-166.
93. De Nardo D, Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol 2011; 32: 373-379.
94. Razani B, Feng C, Coleman T, Emanuel R, Wen H, Hwang S, Ting J, Virgin H, Kastan M, Semenkovich C. Autophagy links inflammasomes to atherosclerotic progression. Cell Metab 2012; 15(4): 534-544.
95. Zhao L, Ding T, Cyrus T, Cheng Y, Tian H, Ma M, Falotico R, Pratico D. Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor. Br J Pharmacol 2009; 156: 774-785.
96. Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang M, Brickey J, Ting J. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011; 12: 408-415.
97. Pope R, Schopp J. The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum 2007; 56 (10): 3183-3188.
98. Kingsbury S, Conaghan P, McDermott M. The role of the NLRP3 inflammasome in gout. J Inflamm Res 2011; 4: 39-49.
99. Lorenz G, Darisipudi M, Anders H. Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol Dial Transplant 2014; 29 (1): 41-48.
100. Iyer S, Pulskens W, Sadler J, Butter L, Teske G, Ulland T, Eisenbarthd S, Florquinc S, Flavelle R, Leemansc J, Sutterwala F. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. PNAS 2009; 106 (48): 20388-20393.
101. Kalantari P, De Oliveira R, Chan J, Corbett Y, Rathinam V, Stutz A, Latz E, Gazzinelli R, Golenbock D, Fitzgerald K. Dual engagement of the NLRP3 and AIM2 inflammasomes by plasmodium-derived hemozoin and DNA during malaria. Cell Rep 2014; 6: 196-210.
102. Shio M, Eisenbarth S, Savaria M, Vinet A, Bellemare M, Harder K, Sutterwala F, Bohle D, Descoteaux A, Flavell R, Olivier M. Malarial hemozoin activates the NLRP3 inflammasome through lyn and syk kinases. PLoS Pathog 2009; 5(8): 1-14.
103. Caorsi R, Lepore L, Zulian F, Alessio M, Stabile A, Insalaco A, Finetti M. Battagliese A, Martini G, Bibalo C, Martini A, Gattorno M. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res Ther 2013; 15:1-8.
104. Lu A, Magupalli V, Ruan J, Yin Q, Atianand M, Vos M, Schrodër G, Fitzgerald K, Wu H, Elegman E. Unified polimerization mechanism for the assembly of ASC-dependent inflammasomes. Cell 2014; 156: 1193-1206.